Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
Conditions
Keywords
Lung Cancer
Brief summary
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) with concurrent chemotherapy in the management of stage II and III non-small cell lung cancer (NSCLC).
Interventions
RADIATIONGenomically Guided Radiation Therapy (RT)
Based on the Radiosensitivity Index (RSI) from testing participants tumor sample, participants will receive either standard dose radiation therapy, which is a strength 60Gy or up to 81Gy strength. Radiation treatment is administered 5 days per week for approximately 6 weeks.
Sponsors
H. Lee Moffitt Cancer Center and Research Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of AJCC Stage 2 or Stage 3 unresectable NSCLC as determined by a multidisciplinary oncology team * Confirmation of NSCLC with availability of fresh tumor biopsy by tissue biopsy which can include adenocarcinoma, squamous cell, large cell carcinoma, or NSCLC not otherwise specified * Life expectancy \>12 weeks * Normal renal (creatinine \<1.5 × upper limit of normal \[ULN\]), liver (bilirubin \< 1.5 × ULN, transaminases \<3.0 × ULN, except in known hepatic disease, wherein may be \<5 × ULN) and blood counts (white blood cells ≥2.5, neutrophils ≥1000, platelets ≥50, 000, hemoglobin ≥8) * ECOG 0-1 * Age ≥ 18 years * Participants with surgery within 14 days should have recovered from all effects of the surgery and be cleared by their surgeon * There is no limit on prior systemic or therapies * Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study * Ability to sign an informed consent form, which can be signed by a family member or health care proxy. Informed consent must be given before any study related procedures occur.
Exclusion criteria
* Current or prior participation in a study of an investigational agent or investigational device within 2 weeks of the first dose of study treatment * Major surgery or significant traumatic injury that has not been recovered from 14 days before the initiation of study drug * Women who are pregnant or breastfeeding * History of allergy or hypersensitivity to any of the study drugs or study drug components * Concurrent brain metastases or leptomeningeal disease * History of prior malignancy within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death (e.g., 5-year OS of \> 90%), such as but not limited to, non-melanoma skin carcinoma, ductal carcinoma in situ, or stage I endometriod uterine cancer, and others at the discretion of the PI * Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[eg, colitis or Crohn's disease\], diverticulitis \[with the exception of diverticulosis\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\]). The following are exceptions to this criterion: * • Patients with vitiligo or alopecia * • Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement * • Any chronic skin condition that does not require systemic therapy * • Patients without active disease in the last 5 years may be included but only after consultation with the Principal Investigator * • Patients with celiac disease controlled by diet alone * Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion: * • Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection) * • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent * • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Unacceptable Toxicity | 12 weeks after start of treatment | Rate of Unacceptable Toxicity will be measured during 12 week period following study enrollment. Unacceptable toxicity is defined as any grade 4 or 5 adverse event (AE) probably or definitely related to experimental dose escalated radiation therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Freedom from local regional progression (FFLRP) | At 2 years | Freedom from local regional progression (FFLRP) will be defined as lack of progression as documented by response assessment imaging following completion of concurrent chemotherapy and radiation. |
| Overall Survival (OS) | At 2 years | Overall Survival (OS) will be measured from the date of first treatment to the date of death due to any cause. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORThomas Dilling, MD
Moffitt Cancer Center
Outcome results
None listed